Multi-center Study on Therapy-oriented Molecular Subtyping of Hepatocellular Carcinoma
|ClinicalTrials.gov Identifier: NCT03668158|
Recruitment Status : Unknown
Verified October 2018 by Xiao Xu, Zhejiang University.
Recruitment status was: Not yet recruiting
First Posted : September 12, 2018
Last Update Posted : October 24, 2018
Information provided by (Responsible Party):
Xiao Xu, Zhejiang University
The purpose of this study is to establish molecular subtyping of HCC.
|Condition or disease|
Hepatocellular carcinoma is one of the most common malignant tumors in the world with high incidence and mortality. Liver transplantation is the most effective treatment for HCC and is in high demand in China. However, recurrence of HCC among liver transplantation recipients is still a great challenge and threat to the survival of recipients. So it is of great significance to establish molecular subtyping of HCC and achieve precise selection of recipients. Based on large scales of samples, the investigator's study aims to establish multi-omics characteristic profiles of liver transplantation for HCC in integration of apparent biological characteristics, clinical management and prognostic information by utilizing genomics, transcriptomics and proteomics, etc. This study will contribute to the therapy-oriented molecular subtyping of HCC.
|Study Type :||Observational|
|Estimated Enrollment :||500 participants|
|Official Title:||Multi-center Study on Therapy-oriented Molecular Subtyping of Hepatocellular Carcinoma|
|Estimated Study Start Date :||November 20, 2018|
|Estimated Primary Completion Date :||May 1, 2020|
|Estimated Study Completion Date :||July 1, 2020|
recurrent HCC after LT
non- recurrent HCC after LT
Primary Outcome Measures :
- recurrence rate [ Time Frame: 2 years ]
No Contacts or Locations Provided